Giuseppina Li Pira

Giuseppina Li Pira

Auto-generated profile, based on publicly available information

Giuseppina Li Pira

Bambino Gesù Children's Hospital, Rome, Italy

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2014 in Blood
Verified
Journal Article
Closed access
PDF file
ABAlice Bertaina
Alice Bertaina
PMPietro Merli
Pietro Merli
SRSergio Rutella
Sergio Rutella
DPDaria Pagliara
Daria Pagliara
MBMaria Ester Bernardo
Maria Ester Bernardo
FLFranco Locatelli
Franco Locatelli
Twenty-three children with nonmalignant disorders received HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) after ex vivo elimination of αβ+ T cells and CD19+ B cells. The median number of CD34+, αβ+CD3+, and B cells infused was 16.8 × 106, 40 × 103, and 40 × 103 cells/kg, respectively. No patient received any posttransplantation pharmacologic prophylaxis for graft-versus-host disease (GVHD). All but 4 patients engrafted, these latter being rescued by a second allograft. Three patients experienced skin-only grade 1 to 2 acute GVHD. No patient developed visceral acute or chronic GVHD. Cumulative incidence of transplantation-related mortality was 9.3%. With a median follow-up of 18 months, 21 of 23 children are alive and disease-free, the 2-year probability of disease-free survival being 91.1%. Recovery of γδ+ T cells was prompt, but αβ+ T cells progressively ensued over time. Our data suggest that this novel graft manipulation strategy is safe and effective for haplo-HSCT. This trial was registered at www.clinicaltrials.gov as #NCT01810120.

3 August 2017 in Blood
Verified
Journal Article
Closed access
PDF file
FLFranco Locatelli
Franco Locatelli
PMPietro Merli
Pietro Merli
DPDaria Pagliara
Daria Pagliara
GPGiuseppina Li Pira
Giuseppina Li Pira
MFMichela Falco
Michela Falco
LMLorenzo Moretta
Lorenzo Moretta
Key Points: Children with AL given haplo-HSCT after αβ T- and B-cell depletion are exposed to a low risk of acute and chronic GVHD and NRM. The leukemia-free, GVHD-free survival of patients given this type of allograft is comparable to that of HLA-matched donor HSCT recipients.

1 January 1991 in Journal of Experimental Medicine
Verified
Journal Article
Open access
FMF Manca
F Manca
DFDaniela Fenoglio
Daniela Fenoglio
GPG Li Pira
G Li Pira
AKA Kunkl
A Kunkl
FCF Celada
F Celada
Activation of a galactosidase-specific murine T hybridoma clone and of a human tetanus toxoid-specific T clone by antigen-presenting cells (APC) was used to evaluate the regulatory function of antibodies complexed with the relevant antigen. Complexed antigen, in fact, is taken up with high efficiency thanks to Fc receptors borne by APC. Antibody/antigen ratio in the complexes proved to be a critical parameter in enhancing antigen presentation. Complexes in moderate antibody excess provided optimal T cell activation independently of the physical state of the complexes (precipitated by a second antibody or solubilized by complement). Complexes in extreme antibody excess, on the contrary, did not yield T cell activation although taken up by APC efficiently. The effect of antibodies at extreme excess was observed with substimulatory dose of antigen (loss of potentiation) and with optimal dose of antigen (loss of stimulation). An excess of specific polyclonal antibodies hampers proteolytic degradation of antigen in vitro, supporting the view that a similar mechanism may operate within the APC that have internalized immune complexes in extreme antibody excess. The possibility that immune complex forming in extreme antibody excess may turn off the T cell response is proposed as a regulatory mechanism.

19 November 2019 in Leukemia
Verified
Journal Article
Closed access
PDF file
CQC. Quintarelli
C. Quintarelli
Simona SivoriSimona Sivori
Simona Sivori
SCS. Caruso
S. Caruso
SCS. Carlomagno
S. Carlomagno
MFM. Falco
M. Falco
FLFranco Locatelli
Franco Locatelli

1 November 2016 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
GPGiuseppina Li Pira
Giuseppina Li Pira
DMDavid Malaspina
David Malaspina
EGElia Girolami
Elia Girolami
SBSimone Biagini
Simone Biagini
ECElisabetta Cicchetti
Elisabetta Cicchetti
FLFranco Locatelli
Franco Locatelli
HLA-haploidentical family donors represent a valuable option for children requiring allogeneic hematopoietic stem cell transplantation (HSCT). Because graft-versus-host diseases (GVHD) is a major complication of HLA-haploidentical HSCT because of alloreactive T cells in the graft, different methods have been used for ex vivo T cell depletion. Removal of donor αβ T cells, the subset responsible for GVHD, and of B cells, responsible for post-transplantation lymphoproliferative disorders, have been recently developed for HLA-haploidentical HSCT. This manipulation preserves, in addition to CD34+ progenitors, natural killer, γδ T, and monocytes/dendritic cells, contributing to anti-leukemia activity and protection against infections. We analyzed depletion efficiency and cell yield in 200 procedures performed in the last 3 years at our center. Donors underwent CD34+ hematopoietic stem cell (HSC) peripheral blood mobilization with granulocyte colony-stimulating factor (G-CSF). Poor CD34+ cell mobilizers (48 of 189, 25%) received plerixafor in addition to G-CSF. Aphereses containing a median of 52.5 × 109 nucleated cells and 494 × 106 CD34+ HSC were manipulated using the CliniMACS device. In comparison to the initial product, αβ T cell depletion produced a median 4.1-log reduction (range, 3.1 to 5.5) and B cell depletion led to a median 3.4-log reduction (range, 2.0 to 4.7). Graft products contained a median of 18.5 × 106 CD34+ HSC/kg recipient body weight, with median values of residual αβ T cells and B cells of 29 × 103/kg and 33 × 103/kg, respectively. Depletion efficiency monitored at 6-month intervals demonstrated steady performance, while improved recovery of CD34+ cells was observed after the first year (P = .0005). These data indicate that αβ T cell and B cell depletion of HSC grafts from HLA-haploidentical donors was efficient and reproducible.

15 June 2010 in Journal of Biomedicine and Biotechnology
Verified
Journal Article
Open access
PDF file
GPGiuseppina Li Pira
Giuseppina Li Pira
FIFederico Ivaldi
Federico Ivaldi
PMPaolo Moretti
Paolo Moretti
FMFabrizio Manca
Fabrizio Manca
Mapping of antigenic peptide sequences from proteins of relevant pathogens recognized by T helper (Th) and by cytolytic T lymphocytes (CTL) is crucial for vaccine development. In fact, mapping of T-cell epitopes provides useful information for the design of peptide-based vaccines and of peptide libraries to monitor specific cellular immunity in protected individuals, patients and vaccinees. Nevertheless, epitope mapping is a challenging task. In fact, large panels of overlapping peptides need to be tested with lymphocytes to identify the sequences that induce a T-cell response. Since numerous peptide panels from antigenic proteins are to be screened, lymphocytes available from human subjects are a limiting factor. To overcome this limitation, high throughput (HTP) approaches based on miniaturization and automation of T-cell assays are needed. Here we consider the most recent applications of the HTP approach to T epitope mapping. The alternative or complementary use of in silico prediction and experimental epitope definition is discussed in the context of the recent literature. The currently used methods are described with special reference to the possibility of applying the HTP concept to make epitope mapping an easier procedure in terms of time, workload, reagents, cells and overall cost.